Navigation Links
QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
Date:10/21/2013

Press-Releases/PressReleaseView/?PressReleaseID=418&lang=EN">EGFR mutations, including the most prevalent resistance mutation, T790M. The test supports efficient laboratory workflow with real-time PCR technology on the FDA approved Rotor-Gene Q MDx, which is part of the QIAsymphony family of laboratory solutions.

The development plan for the companion diagnostic complements Clovis Oncology's accelerated plan for CO-1686 development by potentially allowing a supplemental premarket approval (PMA) filing for the diagnostic. Subject to regulatory approvals, QIAGEN will be responsible for the global development and commercialization of the companion diagnostic, and Clovis will be responsible for the global development and commercialization of CO-1686. The partners also created the framework for possible future collaborations, thereby adding another master agreement to QIAGEN's growing pipeline of collaborations with some of the world's leading pharmaceutical and biotechnology companies. Further terms of the agreement were not disclosed.

"We are pleased to partner with Clovis Oncology in developing a companion diagnostic based on QIAGEN's therascreen technology and to expand the label of our approved therascreen EGFR kit. Together, we can accelerate the development of this important drug candidate and deliver a solution to an unmet medical need," said Peer Schatz, QIAGEN's Chief Executive Officer. "Our therascreen EGFR kit, approved by the FDA based on extensive analytical and clinical data, is the most comprehensive test and offers unique features such as detection of actionable mutations in separate tubes. QIAGEN is a preferred partner in personalized medicine because of our ability to deliver reproducible results, the efficient workflow of our platforms, and our track record in development and regulatory approvals."

"We are pleased to collaborate with QIAGEN for the development of a companio
'/>"/>

SOURCE Qiagen N.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
2. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
3. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
4. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
5. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
6. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
7. WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan
8. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
9. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Leading Non-Fusion Spine Surgeon Supports Company,s Goals for Global ... ... Corporation, a spine care,services organization that partners with hospitals and ... has appointed Dr. Rudolf Bertagnoli, chairman and founder,of ProSpine (Bogen, ...
... Conduct Update Call on Tuesday, August 12, 2008, ... ENMD ), a clinical-stage pharmaceutical company developing,therapeutics ... today,reported financial results for the three and six-month ... ), The Company reported a net ...
... conserve cash while seeking financing/strategic ... ... Bulletin Board: ABOS) announced today that the Company is focusing its,day-to-day ... to preserve the Company,s remaining cash,resources, the Company,s employees were released ...
Cached Biology Technology:SpineMark Appoints Dr. Rudolf Bertagnoli Chairman of International Medical Advisory Board 2EntreMed Reports Second Quarter 2008 Financial Results 2EntreMed Reports Second Quarter 2008 Financial Results 3EntreMed Reports Second Quarter 2008 Financial Results 4EntreMed Reports Second Quarter 2008 Financial Results 5Arbios Announces It Has Suspended Operations 2Arbios Announces It Has Suspended Operations 3Arbios Announces It Has Suspended Operations 4Arbios Announces It Has Suspended Operations 5
(Date:4/23/2014)... Speed-reading is a technique used to read quickly. ... and skipping non-essential words and/ or sentences. Similarly ... pressure to quickly "read" genetic information. Genes that ... as the smaller the encoding message, the easier ... researchers from Instituto Gulbenkian de Cincia (IGC, Portugal) ...
(Date:4/22/2014)... researchers will lead a five-year, $3 million study to ... affecting the transport of dissolved organic matter (DOM) through ... alter the chemical composition and water quality of the ... the National Science Foundation,s MacroSystems Biology program, researchers will ... which begins in Canada and runs through five U.S. ...
(Date:4/22/2014)... PETA International Science Consortium Ltd.,s nanotechnology expert will present ... nanomaterial hazard assessment" at the 7th International Nanotoxicology ... Antalya, Turkey. , Dr. Monita Sharma will outline ... US National Academy of Sciences, " Toxicity Testing in ... which recommends use of non-animal methods involving human cells ...
Breaking Biology News(10 mins):Cell division speed influences gene architecture 2Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3
... study of how weight may affect school attendance, researchers ... found that overweight children are at greater risk of ... of more than a thousand 4th, 5th and 6th ... body mass index, or BMI, is as significant a ...
... Louis, Aug. 10, 2007 Heart disease hits people ... In those with diabetes, cardiovascular complications occur at an ... heart disease the major killer of diabetic people. But ... help answer that question, researchers at Washington University School ...
... - A new imaging technique developed at MIT has allowed ... cell, using a method similar to the X-ray CT scans ... described in a paper published in the Aug. 12 online ... most detailed images yet of what goes on inside a ...
Cached Biology News:Childhood obesity indicates greater risk of school absenteeism, Penn study reveals 2Abnormal fat metabolism underlies heart problems in diabetic patients 2Abnormal fat metabolism underlies heart problems in diabetic patients 3MIT creates 3-D images of living cell 2
... adapter allows the Thermo-Fast® ... AB-1000) PCR plates to ... ABI PRISM® 3700 capillary ... for information on the ...
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
... White lyophilized solid. PROTECT FROM LIGHT. PACKAGED ... of γ-secretase. Equipotently inhibits the release of ... 2.6 μM) and Aβ x-42 (ED ... cells stably transfected with the Amyloid Precursor ...
Biology Products: